Correspondence 0001477932-23-001107 from BioLIfe Sciences Inc (CIK 0001929281)
BioLIfe Sciences Inc (CIK 0001929281)
Date: Feb. 17, 2023 · CIK: 0001929281 · Accession: 0001477932-23-001107
AI Filing Summary & Sentiment
File numbers found in text: 024-11898
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission Post-qualification Amendment No. 2 to Offering Statement on Form 1-A Filed February 9, 2023 and Post-qualification Amendment No. 3 to Offering Statement on Form 1-A (collectively, the "Post-Qualification Amendment") Commission File No. 024-11898
Dear Mr. Crawford:
On behalf of the Company, I respectfully request that the qualification date of the Post-Qualification Amendment be accelerated and that the Post-Qualification Amendment be declared qualified Friday, February 17, 2023, at 4:00 p.m. EST, or as soon thereafter as is reasonably practicable.
In making this request, the Company represents that the Post-Qualification Amendment will be approved in the State of Colorado, upon qualification by the Securities and Exchange Commission (the “Commission”), and acknowledges the following:
-
should the Securities and Exchange Commission (the “Commission”) or the Staff, acting pursuant to delegated authority, declare the filing qualified, it does not foreclose the Commission from taking any action with respect to the filing;
-
the action of the Commission or the staff, acting pursuant to delegated authority, to declare the filing qualified does not relieve the Company from its full responsibility for the adequacy and accuracy of disclosure in the filing; and
-
the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.
Very truly yours,
/s/ Justin De Four
Show Raw Text
CORRESP
1
filename1.htm
blfe_corresp.htm
BioLife Sciences, Inc.
2831 Saint Rose Parkway, Suite 200
Henderson, Nevada 89052
February 17, 2023
VIA EDGAR
Daniel Crawford
Office of Life Sciences
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
BioLife Sciences, Inc. (the “Company”)
Post-qualification Amendment No. 2 to
Offering Statement on Form 1-A
Filed February 9, 2023 and Post-qualification Amendment No. 3 to Offering Statement on Form 1-A (collectively, the "Post-Qualification Amendment")
Commission File No. 024-11898
Dear Mr. Crawford:
On behalf of the Company, I respectfully request that the qualification date of the Post-Qualification Amendment be accelerated and that the Post-Qualification Amendment be declared qualified Friday, February 17, 2023, at 4:00 p.m. EST, or as soon thereafter as is reasonably practicable.
In making this request, the Company represents that the Post-Qualification Amendment will be approved in the State of Colorado, upon qualification by the Securities and Exchange Commission (the “Commission”), and acknowledges the following:
-
should the Securities and Exchange Commission (the “Commission”) or the Staff, acting pursuant to delegated authority, declare the filing qualified, it does not foreclose the Commission from taking any action with respect to the filing;
-
the action of the Commission or the staff, acting pursuant to delegated authority, to declare the filing qualified does not relieve the Company from its full responsibility for the adequacy and accuracy of disclosure in the filing; and
-
the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.
Very truly yours,
/s/ Justin De Four
Justin De Four
Chief Executive Officer
BioLife Sciences, Inc.